Laboratory Tests for Myasthenia Gravis
The essential laboratory workup for suspected myasthenia gravis should include acetylcholine receptor (AChR) antibodies as the first-line test, followed by muscle-specific kinase (MuSK) antibodies if AChR is negative, and then lipoprotein-related protein 4 (LRP4) antibodies if both are negative. 1, 2, 1
Serological Testing Algorithm
First-Line Testing
- AChR antibodies (binding, blocking, or modulating) - This confirms diagnosis in approximately 80% of generalized MG and 50% of ocular MG cases 3, 2, 3
- Expect seronegative results in about 20% of generalized MG and 50% of ocular MG patients 3, 2, 3
Second-Line Testing (if AChR negative)
- MuSK antibodies - Positive in approximately one-third of seronegative patients 3, 2, 3
- Critical for treatment decisions as MuSK-positive patients may respond differently to therapies 2
Third-Line Testing (if both AChR and MuSK negative)
- LRP4 antibodies - Associated with both generalized and ocular MG 3, 2, 3
- Identifies additional 2-50% of seronegative cases 4
Additional Laboratory Studies
Muscle Enzyme Assessment
- Creatine phosphokinase (CPK) - Essential to evaluate for concurrent myositis 1
- Aldolase - Supports differentiation from inflammatory myopathy 1
Inflammatory Markers
- ESR and CRP - Helps assess for possible concurrent inflammatory conditions 1
Cardiac Evaluation (when indicated)
- Troponin T - Required if respiratory insufficiency or elevated CPK present to rule out myocarditis 1
- Note: High-sensitivity troponin T can be elevated in skeletal muscle involvement without cardiac disease 5
Anti-striated Muscle Antibodies
- Should be tested alongside AChR antibodies 1
- Particularly relevant when evaluating for thymoma risk
Critical Testing Considerations
Timing Issues
- MOG antibody concentrations vary with disease activity - Higher during acute attacks, lower during remission or immunosuppression 6
- If initial testing is negative but clinical suspicion remains high, retest during acute exacerbations or treatment-free intervals 6
- Plasma exchange can transiently eliminate antibodies; wait 1-3 months post-treatment before retesting 6
Methodological Approach
The radioimmunoprecipitation assay (RIPA) has been the historical standard but has limitations:
- Sensitivity for AChR: 50-92% (specificity nearly 100%) 4
- Cell-based assays (fixed and live CBA) demonstrate higher sensitivity than RIPA 4
- Recommend complete reflex testing algorithm on first pretreatment sample 4
Common Pitfall
Real-world data shows significant undertesting: among seronegative patients, only 33.7% receive both AChR and MuSK testing, and merely 5% receive all three antibody tests 7. Do not stop at negative AChR results - proceed systematically through the testing algorithm.
Pulmonary Function Assessment
- Negative inspiratory force and vital capacity - Required for all grades of suspected MG 1
- Critical for identifying patients at risk for respiratory compromise, which can be life-threatening
When to Consult Neurology
Neurology consultation is recommended for all suspected MG cases 1, as diagnosis requires integration of clinical findings with laboratory results and often necessitates electrodiagnostic studies (repetitive nerve stimulation and single-fiber EMG) for confirmation 3, 2, 3.